What is it about?
Myo1g is a potential biomarker in pediatric Leukemia, here we developed novel monoclonal antibodies against Myo1g, these antibodies could be used in potential diagostic tests or in confirmation studies as they could help to distinguish between normal and transformed cells
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
Leukemia remains one of the main causes of child death, novel biomarkers could aid in the improvement of patient stratification and better survival probabilities
Read the Original
This page is a summary of: Detection of Myosin 1g Overexpression in Pediatric Leukemia by Novel Monoclonal Antibodies, International Journal of Molecular Sciences, April 2022, MDPI AG,
DOI: 10.3390/ijms23073912.
You can read the full text:
Contributors
The following have contributed to this page
